TIDMAMYT

RNS Number : 2485G

Amryt Pharma PLC

25 May 2017

25 May 2017

AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

Result of AGM

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce that all resolutions proposed at the Company's Annual General Meeting, held today, were duly approved by shareholders.

Enquiries:

 
Amryt Pharma plc                 C/o KTZ Communications 
Joe Wiley, CEO 
 Rory Nealon, CFO/COO 
 
                                 +44 (0) 20 7408 
Shore Capital                     4090 
Nomad and Joint Broker 
Bidhi Bhoma, Edward Mansfield 
 
Davy                             +353 (1) 679 6363 
ESM Adviser and Joint Broker 
John Frain, Anthony Farrell 
 
                                 +44 (0) 20 7710 
Stifel                            7600 
Joint Broker 
Jonathan Senior, Ben Maddison 
 
                                 +44 (0) 20 3178 
KTZ Communications                6378 
Katie Tzouliadis, Emma Pearson

About Amryt Pharma plc

(www.amrytpharma.com)

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the EU and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGEAESSALSXEFF

(END) Dow Jones Newswires

May 25, 2017 06:49 ET (10:49 GMT)

Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Amryt Pharma Charts.
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Amryt Pharma Charts.